التفاصيل البيبلوغرافية
| العنوان: |
Glycovariations in Key HDL‐Associated Glycoproteins Differentiate Between Clinical Groups and Affect the Immunomodulatory Capacity of HDL |
| المؤلفون: |
Zivkovic, Angela M, Krishnan, Sridevi, Shimoda, Michiko, Sacchi, Romina, Muchena, John K, Luxardi, Guillaume, Kaysen, George A, Parikh, Atul N, Ngassam, Viviane, Johansen, Kirsten, Chertow, Glenn, Grimes, Barbara, Smilowitz, Jennifer T, Maverakis, Emanual, Lebrilla, Carlito B |
| المساهمون: |
National Institutes of Health, Burroughs Wellcome Fund |
| المصدر: |
The FASEB Journal ; volume 31, issue S1 ; ISSN 0892-6638 1530-6860 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2017 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
The goal of this pilot study was to determine whether HDL composition, particularly key HDL‐associated glycoproteins, affects HDL immunomodulatory function. HDL were purified from healthy controls (n=13), subjects with metabolic syndrome (MetS) (n=13), and diabetic hemodialysis (HD) patients, who experienced an infectious hospitalization event within 60 days (HD+) (n=12), and those with no event (HD−) (n=12). Concentrations of HDL‐bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein A‐I (ApoA‐I), apolipoprotein C‐III (ApoC‐III), α‐1‐antitrypsin (A1AT), and α‐2‐HS‐glycoprotein (A2HSG); and the site‐specific glycovariations of ApoC‐III, A1AT, and A2HSG were measured. Secretion of interleukin 6 (IL‐6) in stimulated monocytes was measured to assess HDL immunomodulatory capacity. HDL from HD patients were enriched in SAA, LBP, ApoC‐III, disialylated ApoC‐III (ApoC‐III 2 ) and desialylated A2HSG. HDL that increased IL‐6 secretion were enriched in ApoC‐III, disialylated glycans 5402 and 5412 at multiple A1AT glycosites and desialylated A2HSG, and depleted in monosialylated ApoC‐III (ApoC‐III 1 ). HDL from HD+ patients were enriched in SAA but had lower levels of sialylation across glycoproteins. Our results demonstrate that HDL composition, including the site‐specific glycosylations, differentiate between clinical groups, correlate with HDL's ability to modulate LPS‐induced monocyte IL‐6 response, and may be predictive of HDL's ability to protect from infection. Support or Funding Information This research project was supported by NIH R01GM049077 (CBL), the UC Davis Clinical and Translational Research Center NIH grant # UL1 TR000002 (AMZ), and by the Burroughs Wellcome Fund and a grant from the NIH 1DP2OD008752 (EM) contracts N01‐DK‐7‐0005 and N01‐DK‐7‐5004 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and a K24DK085153 grant. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1096/fasebj.31.1_supplement.655.2 |
| الإتاحة: |
https://doi.org/10.1096/fasebj.31.1_supplement.655.2Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.84E2A2F2 |
| قاعدة البيانات: |
BASE |
